Positron emission tomography for the assessment of myocardial viability

Ontario Health Technology Assessment Series

Volumn 10, Issue 16, 2010, Pages 1-80

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955732315     PISSN: 19157398     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Medical Advisory Secretariat and Ontario Ministry of Health and Long-Term Care. Positron emission tomography for the assessment of myocardial viability [Internet]. 2005. [cited: 2009 Dec 29]. Available from: http://www.health.gov. on.ca/english/providers/program/mas/mas-mn.html
2. Heart and Stroke Foundation of Ontario. Statistics [Internet]. [updated 2009; cited 2009 Dec 14]. Available from: http://www.heartandstroke.on.ca/site/ c.pvI3IeNWJwE/b.3581729/k.359A/Statistics.htm#heartdisease
3. Schinkel AF, Bax JJ, Poldermans D. Clinical assessment of myocardial hibernation. Heart 2005; 91(1):111-7.
4. Bax JJ, van der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart 2004; 90 Suppl 5:v26-v33. (Pubitemid 38998270)
5. Chow CM, Donovan L, Manuel D, Johansen H, Tu JV. Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol 2005; 21(14):1265-71. (Pubitemid 43174606)
6. Senior R. Diagnostic and imaging considerations: role of viability. Heart Fail Rev 2006; 11(2):125-34. (Pubitemid 44288727)
7. Underwood SR, Bax JJ, vom DJ, Henein MY, Knuuti J, van Rossum AC et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004; 25(10):815-36.
8. Lalonde L, Ziadi MC, Beanlands R. Cardiac positron emission tomography: current clinical practice. Cardiol Clin 2009; 27(2):237-55.
9. Rizzello V, Poldermans D, Bax JJ. Assessment of myocardial viability in chronic ischemic heart disease: current status. Q J Nucl Med Mol Imaging 2005; 49(1):81-96. (Pubitemid 41568194)
10. Ghesani M, Depuey EG, Rozanski A. Role of F-18 FDG positron emission tomography (PET) in the assessment of myocardial viability. Echocardiography 2005; 22(2):165-77. (Pubitemid 40205113)
11. Tomlinson DR, Becher H, Selvanayagam JB. Assessment of myocardial viability: comparison of echocardiography versus cardiac magnetic resonance imaging in the current era. Heart Lung Circ 2008; 17(3):173-85.
12. Kim RJ, Wu E, Rafael A, Chen E-L, Parker MA, Simonetti OP et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445-53.
13. Strzelczyk J, Attili A. Cardiac magnetic resonance evaluation of myocardial viability and ischemia. Semin Roentgenol 2008; 43(3):193-203. (Pubitemid 351681909)
14. Di Carli MF, Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease. Circulation 2007; 115(11):1464-80. (Pubitemid 46648384)
15. Chacko GN. PET imaging in cardiology. Hell J Nucl Med 2005; 8(3):140-4.
16. Health Canada. Medical devices active licence listing [Internet]. [updated 2009 Feb 19; cited 2009 Oct 8]. Available from: http://webprod.hc-sc. gc.ca/mdll-limh/dispatch-repartition.do?type=active&lang=eng
17. Ontario Ministry of Health and Long-Term Care. Bulletin 4498 [Internet]. [updated 2009 Sep 30; cited 2009 Dec 22]. Available from: www.health.gov.on.ca/ english/providers/program/ohip/bulletins/4000/bul4498.pdf
18. Beanlands R. Information and contacts: Ontario Cardiac FDG PET Registry (CADRE) [Internet]. [updated 2008 Mar 25; cited 2009 Dec 22]. Available from: www.ottawaheart.ca/UOHI/doc/CADRE-intro.pdf
19. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol 2006; 59(12):1331-2. (Pubitemid 44708615)
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57(1):289-300.
21. Jaeschke R, Guyatt GH, Sackett DL, the Evidence-Based Medicine Working Group. How to use an article about a diagnostic test [Internet]. [updated 2007 Aug 15; cited 2009 Nov 23]. Available from: http://www.cche.net/usersguides/ diagnosis.asp
22. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3:25.
23. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7:10. (Pubitemid 46364967)
24. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490.
25. Goodman C. Literature searching and evidence interpretation for assessing health care practices. Stockholm, Sweden: Swedish Council on Technology Assessment in Health Care. 1996. 81 p. SBU Report No. 119E.
26. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007; 32(7):375-410. (Pubitemid 46881171)
27. Beanlands RS, Chow BJ, Dick A, Friedrich MG, Gulenchyn KY, Kiess M et al. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease--executive summary. Can J Cardiol 2007; 23(2):107-19. (Pubitemid 46655426)
28. Beanlands R. S., Chow B. J., Dick A., Friedrich M. G., Gulenchyn K. Y., Kiess M.et al. CCS / CAR / CANM / CNCS / Can SCMR joint position statement on advanced non-invasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multi-detector computed tomography angiography in the diagnosis and evaluation of ischemic heart disease [Internet]. Ottawa, ON: Canadian Cardiovascular Society. 2006. [cited: 2009 Aug 26]. 48 p. Available from: http://www.ccs.ca/download/position-statements/cardiac-imaging-Dec11- appen-tables.pdf
29. Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001; 26(2):147-86.
30. Kuhl HP, Lipke CS, Krombach GA, Katoh M, Battenberg TF, Nowak B et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol. Eur Heart J 2006; 27(7):846-53.
31. Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Irwan R, Sluiter WJ et al. Prediction of functional recovery after revascularization in patients with chronic ischaemic left ventricular dysfunction: head-to-head comparison between 99mTc-sestamibi/18F-FDG DISA SPECT and 13N-ammonia/ 18F-FDG PET. Eur J Nucl Med Mol Imaging 2006; 33(6):716-23. (Pubitemid 43846764)
32. Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Dierckx RA, de BJ et al. Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. J Nucl Cardiol 2006; 13(2):210-9.
33. Barrington SF, Chambers J, Hallett WA, O'Doherty MJ, Roxburgh JC, Nunan TO. Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging 2004; 31(3):355-61. (Pubitemid 38314079)
34. Schmidt M, Voth E, Schneider CA, Theissen P, Wagner R, Baer FM et al. F-18-FDG uptake is a reliable predictory of functional recovery of akinetic but viable infarct regions as defined by magnetic resonance imaging before and after revascularization. Magn Reson Imaging 2004; 22(2):229-36. (Pubitemid 38326642)
35. Nowak B, Schaefer WM, Koch KC, Kaiser HJ, Block S, Knackstedt C et al. Assessment of myocardial viability in dysfunctional myocardium by resting myocardial blood flow determined with oxygen 15 water PET. J Nucl Cardiol 2003; 10(1):34-45. (Pubitemid 36335850)
36. Bax JJ, Fath-Ordoubadi F, Boersma E, Wijns W, Camici PG. Accuracy of PET in predicting functional recovery after revascularisation in patients with chronic ischaemic dysfunction: head-to-head comparison between blood flow, glucose utilisation and water-perfusable tissue fraction. Eur J Nucl Med Mol Imaging 2002; 29(6):721-7. (Pubitemid 34591687)
37. Lund GK, Freyhoff J, Schwaiger M, Lubeck M, Lund CH, Buchert R et al. Prediction of left ventricular functional recovery by dobutamine echocardiography, F-18 deoxyglucose or 99mTc sestamibi nuclear imaging in patients with chronic myocardial infarction. Cardiology 2002; 98(4):202-9.
38. Gerber BL, Ordoubadi FF, Wijns W, Vanoverschelde JL, Knuuti MJ, Janier M et al. Positron emission tomography using(18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Positron Emission Tomography for the Detection of Myocardial Viability. Eur Heart J 2001; 22(18):1691-701.
39. Tani T, Teragaki M, Watanabe H, Muro T, Yamagishi H, Akioka K et al. Prediction of functional recovery in patients with myocardial infarction after revascularization - comparison of low-dose dobutamine stress echocardiography with fluorine-18 fluorodeoxyglucose positron emission tomography. Jpn Circ J 2001; 65(3):177-81. (Pubitemid 32225197)
40. Wiggers H, Nielsen TT, Bottcher M, Egeblad H, Botker HE. Positron emission tomography and low-dose dobutamine echocardiography in the prediction of postrevascularization improvement in left ventricular function and exercise parameters. Am Heart J 2000; 140(6):928-36.
41. Fath-Ordoubadi F, Beatt KJ, Spyrou N, Camici PG. Efficacy of coronary angioplasty for the treatment of hibernating myocardium. Heart 1999; 82(2):210-6. (Pubitemid 29362873)
42. Schoder H, Campisi R, Ohtake T, Hoh CK, Moon DH, Czernin J et al. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. J Am Coll Cardiol 1999; 33(5):1328-37.
43. Pagano D, Bonser RS, Townend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 1998; 79(3):281-8. (Pubitemid 28212218)
44. Maes AF, Borgers M, Flameng W, Nuyts JL, van de WF, Ausma JJ et al. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up. J Am Coll Cardiol 1997; 29(1):62-8. (Pubitemid 27028721)
45. Baer FM, Voth E, Deutsch HJ, Schneider CA, Horst M, de Vivie ER et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol 1996; 28(1):60-9. (Pubitemid 26266623)
46. Gerber BL, Vanoverschelde JL, Bol A, Michel C, Labar D, Wijns W et al. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996; 94(4):651-9.
47. vom Dahl J., Altehoefer C, Sheehan FH, Buechin P, Uebis R, Messmer BJ et al. Recovery of regional left ventricular dysfunction after coronary revascularization. Impact of myocardial viability assessed by nuclear imaging and vessel patency at follow-up angiography. J Am Coll Cardiol 1996; 28(4):948-58.
48. Carrel T, Jenni R, Haubold-Reuter S, von SG, Pasic M, Turina M. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992; 6(9):479-84.
49. Marwick TH, Nemec JJ, Lafont A, Salcedo EE, MacIntyre WJ. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol 1992; 69(9):854-9.
50. Zhang X, Liu X, Shi R, Wu Q, Gao R, Liu Y et al. Evaluation of the clinical value of combination of 99mTc-MIBI myocardial SPECT and 18F-FDG PET in assessing myocardial viability. Radiat Med 1999; 17(3):205-10. (Pubitemid 29330353)
51. Grandin C, Wijns W, Melin JA, Bol A, Robert AR, Heyndrickx GR et al. Delineation of myocardial viability with PET. J Nucl Med 1995; 36(9):1543-52.
52. Desideri A, Cortigiani L, Christen AI, Coscarelli S, Gregori D, Zanco P et al. The extent of perfusion-F18- fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2005; 46(7):1264-9. (Pubitemid 41615547)
53. Feola M, Biggi A, Chauvie S, Vado A, Leonardi G, Rolfo F et al. Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemic myocardial dysfunction: a perfusion-metabolism positron emission tomography study. Nucl Med Commun 2008; 29(5):448-54. (Pubitemid 351509345)
54. Sawada S, Hamoui O, Barclay J, Giger S, Fain R, Foltz J et al. Usefulness of positron emission tomography in predicting long-term outcome in patients with diabetes mellitus and ischemic left ventricular dysfunction. Am J Cardiol 2005; 96(1):2-8. (Pubitemid 40853929)
55. Rohatgi R, Epstein S, Henriquez J, Ababneh AA, Hickey KT, Pinsky D et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol 2001; 87(9):1096-9, A6. (Pubitemid 32710325)
56. Zhang X, Liu XJ, Wu Q, Shi R, Gao R, Liu Y et al. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial (99m)Tc-MIBI SPECT and (18)F-FDG PET. J Nucl Med 2001; 42(8):1166-73. (Pubitemid 32717833)
57. Di Carli MF, Maddahi J, Rokhsar S, Schelbert HR, Bianco-Batlles D, Brunken RC et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 1998; 116(6):997-1004. (Pubitemid 28553544)
58. vom DJ, Altehoefer C, Sheehan FH, Buechin P, Schulz G, Schwarz ER et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 1997; 38(5):742-8.
59. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994; 90(6):2687-94.
60. Eitzman D, al-Aouar Z, Kanter HL, vom DJ, Kirsh M, Deeb GM et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992; 20(3):559-65.
61. D'Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009; 2(9):1060-8.
62. Marwick TH, Zuchowski C, Lauer MS, Secknus MA, Williams J, Lytle BW. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol 1999; 33(3):750-8.
63. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007; 50(20):2002-12. (Pubitemid 350054917)
64. Martins Felix RC, Correa PL, de Azevedo JC, Da Rocha Dohmann HF, Mesquita ET, Mesquita CT. Clinical impact of positron emission tomography by coincidence system with 18F-FDG on therapeutic decision-making of patients with ischemic cardiomyopathy after myocardial infarction. Arq Bras Cardiol 2006; 86(5):337-45.
65. Siebelink HM, Blanksma PK, Crijns HJ, Bax JJ, van Boven AJ, Kingma T et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 2001; 37(1):81-8. (Pubitemid 32051722)
66. Beanlands RS, deKemp RA, Smith S, Johansen H, Ruddy TD. F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function. Am J Cardiol 1997; 79(8):1092-5.
67. Haas F, Haehnel CJ, Picker W, Nekolla S, Martinoff S, Meisner H et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30(7):1693-700.
68. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1):1-12.
69. Thompson RC, Cullom SJ. Issues regarding radiation dosage of cardiac nuclear and radiography procedures. J Nucl Cardiol 2006; 13(1):19-23.
70. International Commission on Radiological Protection. Recommendations of the ICRP. ICRP publication 103. Ottawa, ON: Elsevier; 2008.
71. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. ICRP publication 80. Ottawa, ON: Elsevier; 1999.